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Introduction
Kidney transplantation is the preferred treatment method
for patients suffering from end-stage renal diseases.
Delayed graft function (DGF) is the main risk factor for
shortened allograft survival and acute rejection is more
frequent in allografts with DGF [1]. The incidence of
DGF – defined as need for more than one dialysis within
the first week after transplantation – is roughly 25% in
transplant recipients from deceased donors [1]. Despite
improvements in immunosuppressive therapy, this high
rate remained unchanged in recent years.
Several possible risk factors have been identified for
DGF such as donor age, the amount of panel reactive
antibodies, prolonged cold ischemic time, low pretrans-
plant mean arterial blood pressure (<100 mmHg) in the
recipient, or transplantation of kidneys from female
donors to male recipients. Cold ischemic time is only a
minor confounder for graft survival if it is <1 day [2].
Next to these clinical risk factors, it has been shown that
deceased donor kidneys with subsequent postischemic
DGF exhibit an activation of genes belonging to the
immune response, cell communication, and apoptosis
superfamilies [3].
In current clinical practice, DGF is typically diagnosed
by serum creatinine concentration measurements. Unfor-
tunately, serum creatinine is an unreliable indicator dur-
ing acute changes in kidney function. The quest to
improve early diagnosis of DGF is an area of intense
research [4].
Various immunologic and nonimmunologic patho-
mechanisms have been discussed in the literature to be
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Summary
The aim of this study was to assess gene expression levels of four biomarker
candidates [lipocalin 2 (LCN2), the kidney injury molecule 1 (HAVCR1),
netrin 1, and the cysteine-rich, angiogenic inducer, 61] in the tubulointerstitial
and the glomerular compartment of zero-hour kidney biopsies in order to pre-
dict developing delayed graft function (DGF). Thirty-four needle kidney biopsy
samples of deceased donors were manually microdissected. Relative gene
expression levels were determined by real-time RT-PCR. For the validation of
the biomarker candidates, we calculated a mixed model comparing kidneys
with DGF, primary function and control samples from the healthy parts of
tumor nephrectomies. Significant biomarker candidates were analyzed together
with donor age in multivariable regression models to determine the prognostic
value. Expression levels of LCN2 and HAVCR1 in the tubulointerstitium were
significantly upregulated in the DGF group (LCN2: fold change = 3.78,
P = 0.031 and HAVCR1: fold change = 3.44, P = 0.010). Odds ratios of both
genes could not reach significance in the multivariable model together with
donor age. The area under the curve of the receiver operating characteristic
ranges between 0.75 and 0.83. LCN2 and HAVCR1 gene expression levels in
zero-hour biopsies show potential to act as early biomarkers for DGF.
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responsible for cellular damage in renal allografts [3,5].
Microdissection of circumscribed nephron segments in
kidney biopsies has been demonstrated to be an impor-
tant tool in renal gene expression analysis due to the
complex architecture of the kidney [6].
For this study, the expression of four candidate genes,
which are associated with cellular damage, was studied in
renal allografts developing DGF. We found four reported
biomarkers, which are already associated with DGF. Kid-
ney injury molecule 1 (KIM1, also known as HAVCR1) is
a transmembrane type I epithelial cell protein with Ig-like
and mucin domains in its ectodomain and is believed to
play a role in tubulointerstitial damage. KIM-1 is nonde-
tectable in normal kidneys but tubular KIM-1 expression
was observed in human renal biopsies after ischemic or
toxic acute tubulus necrosis. KIM-1 was upregulated in
protocol biopsies with acute tubular injury and is cur-
rently under investigation as a single molecular biomarker
to predict acute kidney injury (AKI) at an early stage
[7,8]. Neutrophil gelatinase-associated lipocalin (NGAL,
also known as lipocalin 2 or LCN2) is currently the most
promising novel biomarker. Human NGAL was originally
identified as a 25-kD protein covalently bound to gelati-
nase in neutrophils. It is normally expressed in very low
levels in several human tissues, including those of the kid-
ney, lungs, stomach, and colon. NGAL expression is
markedly induced in injured epithelia. Several studies
focused on NGAL as the novel biomarker for AKI. Micro-
array analysis showed that NGAL is one of the earliest
and most robustly induced gene and protein in the kid-
ney after ischemic or nephrotoxic injury in animal models
[9–11]. Both plasma and urine NGAL concentrations
were shown to highly correlate with serum creatinine
concentrations. Kidney biopsies in these patients with
DGF showed intense accumulation of immuno-reactive
NGAL in 50% of the cortical tubules [10–12]. Moreover,
the secreted, cysteine-rich, heparin-binding protein
CYR61 might serve as an early biomarker of renal injury.
CYR61 is rapidly induced in proximal straight tubuli fol-
lowing renal ischemia and it is excreted in the urine [13].
CYR61 is a secreted, cysteine-rich, heparin-binding pro-
tein encoded by a growth factor-inducible immediate-
early gene [14]. CYR61 promotes the endothelial cells
through interaction with integrin and augments growth
factor-induced DNA synthesis in the same cell type. It is
an extracellular matrix-associated signaling molecule that
functions in cell migration, adhesion, and differentiation.
In human kidney, CYR61 expression is confined to podo-
cytes in normal human adult and embryogenic glomeruli
from the capillary loop stage. Downregulation of CYR61
was significantly greater in diseased kidneys with severe
mesangial expansion. Netrin-1 is a laminin-like molecule
and all the three isoforms of netrin (1, 3, 4) are expressed
in the normal kidney. Reeves et al. analyzed the urinary
netrin-1 excretion after ischemia–reperfusion injury in
mice. Urinary netrin-1 levels increased markedly within
3 h after ischemia–reperfusion injury, reached a peak level
at 6 h and then decreased, returning to baseline within
72 h. Serum creatinine rose significantly just after 24 h of
reperfusion. High levels of netrin 1 (NTN1) could be
detected in urine of 13 acute renal failure patients, whereas
in six healthy volunteer urine samples the protein level was
under the detection threshold. Immunohistochemical
localization showed that netrin-1 is highly expressed in
tubular epithelial cells in transplanted human kidneys.
Therefore, the authors conclude that urinary netrin-1 is a
promising early biomarker of renal injury [15].
The aim of our study was to compare the gene expres-
sion levels of these four candidate genes in the mixed cell
populations found in microdissected zero-hour needle
biopsies within the tubulointerstitial and the glomerular
part classified in DGF and primary function (PF).
Materials and methods
Biomarker selection
The four biomarker candidates NGAL (also known as
lipocalin 2 or LCN2), netrin 1 (NTN1), CYR61, and the
KIM1 (also known as HAVCR1) were selected for the
evaluation of gene expression levels in the tubulointersti-
tial and glomerular part of the kidney.
In addition, the expression levels of podocin (NPHS2)
and the solute carrier family 34 sodium phosphate mem-
ber 1 (SLC34A1) were determined because of their high
expression levels in the glomerular and tubular compart-
ments respectively. NPHS2 expression is restricted to the
podocytes in the glomerular part and acts as a linker
between the plasma membrane and the cytoskeleton
[16,17]. The main function of SLC34A1 is the phosphate
reabsorption in the renal proximal tubuli in the brush
border membrane [18].
Samples and clinical data
Zero-hour needle biopsies from renal transplant patients
were used. Seventeen samples from patients experiencing
DGF and 17 samples from patients with PF were obtained
based on a sample size calculation to detect a difference
of 2.58 cycles (fold change >6) with a power of 80% and
a = 0.05. DGF was defined as need for more than one
dialysis within the first week after kidney transplantation.
Samples from the 34 deceased heart beating donors were
obtained from the Department of Transplantation and
Surgery of Semmelweis University, Budapest. The study
was approved by the local Institutional review board
(Ethical Committee of the Medical University of Vienna #
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EK-067/2005, to be found at http://ohrp.cit.nih.gov/search
and the Semmelweis University, Budapest). During organ
procurement, donor organ kidneys were perfused with a
4 C histidine–tryptophan ketoglutarate preservation solu-
tion. Sterile needle kidney biopsies were obtained from
donor kidneys just before the transplantation using a 18-
gauge needle. The core was immediately submerged into
RNAlater (Ambion, Austin, TX, USA) prefilled 2 ml
Eppendorf tubes and stored at 4 C till the next day when
it was cooled to )80 C and stored until RNA extraction.
Donor data were collected retrospectively, whereas data of
the transplant recipients were prospectively collected. The
decision to initiate dialysis was at the discretion of the
attending physicians, without involvement of study inves-
tigators.
Nine samples from the unaffected areas of tumor
nephrectomy specimens were used as control group as was
previously demonstrated by Higgins et al. [19] (Ethical
Committee of the KH Elisabethinen Linz # EK-325/2008).
Manual microdissection, RNA extraction and reverse
transcription
To separate glomerular part from the tubulointerstitial
part, we used manual microdissection. The biopsies were
thawed on ice and then transferred to a Petri dish contain-
ing ice-cold RNAlater 1:10 dilution. The biopsies were mi-
crodissected using two needles under a reflecting light
microscope (Bresser, #58-04000, Rhede, Germany) [6] to
separate the glomerular part from the tubulointerstitial
part. The number of glomeruli per biopsy was between 10
and 15. Separated glomeruli and the tubulointerstitial tissue
were transferred into a 1.5-ml Eppendorf tube containing
1 ml TRIzol (Invitrogen, Carlsbad, CA, USA). Marking
our RNA pellet, we used 0.5 ll GlycoBlue (Applied Biosys-
tem, Ambion) [20]. The RNA concentration was measured
using a NanoDrop Spectrophotometer (ND 1000; PeqLab;
Biotechnology GmbH). Synthesizing single-stranded cDNA
was according to the protocol of High Capacity RT Kit.
(Applied Biosystem, Foster City, CA, USA).
Preamplification and real-time polymerase chain reaction
Because of the small amount of cDNA, a multiplex pre-
amplification was necessary to increase the quantity of
the desired specific cDNA targets for gene expression
analysis. Pooling our target gene assays, 10 cycles of pre-
amplification were performed combining 5 ll from the
cDNA with the PreAmp Master Mix (TaqMan PreAmp
Master Mix Kit; Applied Biosystem) according to the pre-
amplification protocol.
Real-time PCR was performed using the TaqMan Gene
Expression Master Mix, TaqMan Gene expression assays
(LCN2: Hs00194353_m1, HAVCR1: Hs00273334_01,
CYR61: Hs00155479_m1 and NTN1: Hs00924151_m1)
and the ABI 7300 Real-Time PCR System. All instruments
and reagents were purchased from Applied Biosystems.
Relative gene expression values were evaluated by the
2DDCt method using PPIA [peptidylprolyl isomerase A
(cyclophilin A), Hs99999904_m1] as housekeeping gene
and Stratagene Universal human reference RNA (Strata-
gene, La Jolla, CA, USA) as reference RNA. qRT-PCR con-
ditions were set according to the manufacturer’s
recommendations: 10 min at 95 C, 40 cycles (15 s at
95 C, 1 min at 60 C) with fluorescence reading during
annealing step.
Statistical analysis
For demographic data, median and interquartile ranges
were computed and the Wilcoxon test was used for evalu-
ation of significance between the groups under study. For
discrete clinical parameters, either the chi-square or Fish-
er’s exact test was used.
Statistical differences between expression levels of
groups (PF versus DGF as well as control group versus
transplanted patients) were computed as contrasts in a
mixed model in which compartment, group assignment
and interaction between these variables are independent
variables. A diagonal structure was used for the covari-
ance matrix. A P-value <0.05 was considered statistically
significant.
Logistic regression analysis
Multivariable logistic regression analysis was performed
to identify the best combination of clinical and molecular
parameters allowing a prediction of DGF. The discrimi-
native power of parsimonious models was evaluated
using c-statistics area under the curve (AUC). A molecu-
lar model including the discriminating genes and a
c-statistics was calculated. Further validation of the model
was performed by evaluating the reproducibility of the
discrimination of patients of the same population. There-
fore, a 34-fold cross-validation was computed. The AUC
is defined by the Sommer’s D-statistics [AUC =
(1 + Sommer’s D)/2]. In a final approach, a combination
of clinical and molecular variables was used to obtain the
best possible prediction, discrimination and model fitness
statistics using the Hosmer–Lemeshow goodness-of-fit
test. The analysis was conducted using sas for Windows
9.2 (The SAS Institute, Inc., Cary, NC, USA).
Supplemental data can be found at our laboratory web-
page at http://www.meduniwien.ac.at/nephrogene/data/
dgf_marker/.
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Results
Patients’ demographics
The demographic data of the deceased donors as well as
the transplant recipients are provided in Table 1. A signif-
icant difference in donor age (P = 0.005) and last creati-
nine value (P = 0.011) was observed between samples in
the DGF and the PF group.
Biomarker validation
Gene expression of NPHS2, expressed only in the glomer-
ular compartment of the kidney, in the tubulointerstitium
was in the mean 1024 times less (mean 10 cycles, stan-
dard deviation three cycles) compared with the glomeru-
lar compartment of the same sample. Against no or too
less difference in gene expression of SLC34A1 between the
two compartments could be detected. SLC34A1 is only
expressed in proximal tubuli cells. Manual microdissec-
tion was only efficient to purify the tubulointerstium
from glomeruli. Therefore, data only of the tubulointer-
stitium were used for the biomarker validation.
The two marker proteins NGAL and KIM1 were signif-
icantly upregulated in the DGF group compared with the
PF in the tubulointerstitium. NGAL was upregulated by a
factor of 3.78 [P = 0.031; (h) Fig. 1] in the group of
samples experiencing DGF. KIM1 also showed higher
expression values in the DGF group [fold change = 3.44,
P = 0.010; (+) Fig. 1]. Expression levels of these two
genes in the nine control samples (tumor nephrectomy
samples) were significantly lower compared with the
transplant biopsies [NGAL P < 0.001, (s) Fig. 1; KIM1
P < 0.001, (*) Fig. 1]. No significant differences between
the groups under study could be detected for the other
two marker candidates, namely CYR61 and NTN1. A
graphical representation of expression values of the four
biomarker candidates is given in Fig. 1.
Performance of biomarkers
Combinations of the two significant biomarkers were
selected for building logistic regression models. The
results of the multivariable model including donor age
and the molecular biomarkers are given in Table 2. The
AUC of the receiver operating characteristic (ROC)
derived by applying this regression model was found as
0.83 indicating a discrimination between DGF and PF
based on these few predictors (Fig. 2).
The AUCs of ROC of the regression models including
only the two molecular predictors on one hand or donor
age alone on the other hand were 0.80 and 0.78, respec-
tively.
The optimism of the models defined as difference
between training and test sets was generally below 10%
Table 1. Demographic data of trans-
plant donors and recipients stratified by
treatment assignment. Continuous data
are provided as median (first quartile,
third quartile), and categorical data are
given as counts.
PF group DGF group P-value
Number of donors 24 NA
Number of donor organs 17 17 NA
Donor age (years) 44.0 (39, 47) 50.0 (45, 60) 0.005
Donor gender (f/m) 9/8 4/13 0.078
Last creatinine of donor (mg/dl) 0.82 (0.65, 1.01) 1.34 (0.92, 1.57) 0.011
Vasopressors used (n/years) 2/15 5/12 0.203
Multiorgan donors (n/years) 14/3 13/4 1.000*
Cause of death (trauma/
intracranial hemorrhage)
5/12 2/15 0.398*
Number of recipients 17 17 NA
Recipient age (years) 47.7 (28.82, 56.71) 51.6 (42.87, 59.82) 0.302
Recipient gender (f/m) 5/12 7/10 0.473
Transplant number (1/2/3) 15/2/0 13/31 0.656*
Cold ischemic time (hours) 18.6 (15.26, 23.10) 19.3 (16.24, 22.35) 0.757
PRA latest (%) 0.0 (0.0, 0.0) 0.0 (0.0, 5.0) 0.521
Sum of HLA
mismatches (0/1/2/3/4/5/6)
1/0/4/9/3/0 0/1/2/8/4/2 0.560*
Number of dialysis treatment
(0/1/2/3/4/5)
17/0/0/0/0/0 0/0/10/4/1/2 <0.001*
Immunosuppression (CNI/else) 17/0 17/0 NA
Induction therapy
(none/anti-CD25/ATG)
10/6/1 12/5/0 0.721
PF, primary function; DGF, delayed graft function; NA, not applicable.
*Fisher’s exact test.
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(Table 3a). The Hosmer–Lemeshow goodness-of-fit test
indicated good calibration of the models, i.e. the number
of expected to observed events was not statistically differ-
ent (P = 0.76; Table 3b).
Further combinations of clinical variables (penal reactive
antibody, cold ischemic time, last donor creatinine, donor
age) in the multivariable logistic regression model can be
found in Tables S2 and S3 (Supporting Information).
Discussion
In the present study, we compared the gene expression
levels of four potential AKI markers in 34 microdissected
needle biopsies from zero-hour renal biopsies which 17
developed DGF after transplantation.
Microdissection together with qRT-PCR is an elegant
tool for the analysis of gene expression of circumscribed
structures of the kidney [21]. Normalization with an
endogenous control gene, such as cyclophilin A, is the
Figure 1 Box–Whisker plots of the four
biomarkers in the tubulointerstitium.
Boxplots show the median and the 1.5
interquartile range of the log2 (relative
expression) measured in the qRT-PCR
experiment. A value of zero equates
same expression level as in the reference
RNA.
Table 2. Multivariable logistic regression model. The discriminative
power of this model is indicated by a c-statistics of 0.83 (AUC). Given
is the odds ratio (OR), the confidence interval (CI), and the P-values.
Predictors OR 95% CI P-value
Donor age (per year) 1.108 1.005 1.221 0.040
LCN2 (AU) 1.269 0.851 1.890 0.242
HAVCR1 (AU) 1.443 0.943 2.208 0.091
AUC, area under the curve; LCN2, lipocalin 2; HAVCR1, kidney injury
molecule 1; AU, arbitrary units (log2-ratio of the amount of mRNA as
found in the sample with respect to the concentration of the
respective mRNA given by the universal reference mRNA used in the
qRT-PCR experiments).
Figure 2 ROC curves: Discrimination for DGF after transplantation
using donor age (solid line), expression features (dashed line), or the
combination of both (dash-dotted line).
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gold standard to allow precise comparison of biological
samples after microdissection [22].
So far, no other study investigated the gene expression
of LCN2, HAVCR1, CYR61, and NTN1 in the tubuloin-
terstitium of the kidney. Univariable analysis showed a
significant upregulation of LCN2 and HAVCR1 in biop-
sies developing DGF in our dataset, whereas donor age
was a major factor according to the multivariable regres-
sion analysis. Donor age is one of the main confounding
factors of DGF but not all grafts from old donors have
necessarily poor graft function. Markers of biological age
have been discussed by Koppelstaetter et al. [23] and may
have the potential of providing a much better forecast
model for renal transplant function.
Two limitations of the technique became apparent dur-
ing the study. First, manual microdissection was not able
to separate glomeruli from the tubulointerstitium ade-
quately. The difference in gene expression levels of
SLC34A1, the specific marker for the tubulointerstitium,
between the two compartments was too low, indicating
that the glomerular part was contaminated with tubuloin-
terstitium. However, we could purify the tubulointersti-
tium, which was used for further analysis. The gene
expression level of the specific marker of the glomerular
part (NPHS2) showed in the mean 10 cycles of difference
between the two compartments and the variation was less.
Second, a considerable range of expression was observed,
represented by the 1.5 interquartile range of the log2 rela-
tive expression. This variation is probably a consequence
of the nature of the heterogeneous patient population. To
exclude that this variation is caused by technical variance,
mRNA expression on consecutive sections from the same
nephrectomy tissue sample was compared. The stringent
correlation obtained demonstrated the reproducibility of
the RNA isolation, preamplification and qRT-PCR (Figs
S1 and S2).
The immediate translation of our findings into clinical
practice would require a full genomics infrastructure at
the transplantation center. As this is likely not available
in most centers, further studies need to test the applica-
bility of our findings using whole biopsies and evaluate
the correlation with protein levels of the biomarkers
determined in plasma or urine.
Taken together, this is the first study reporting gene
expression levels of LCN2, HAVCR1, NTN1, and CYR61
in the tubulointerstitium of zero-hour kidney biopsies
developing DGF. Significant upregulation of LCN2 and
HAVCR1 could be detected in the DGF group by a mixed
model. However, in the multivariable regression model,
the odds ratios of the two biomarkers could not reach
significance. The prognostic value of the two biomarkers
together with donor age ranges between 75% and 83%.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table 3. Discrimination of the models and optimism (a) derived from
the re-sampling procedure (34-fold cross-validation). Calibration of
the DGF prediction model by the Hosmer–Lemeshow goodness-
of-fit test (b). The expected to observed number of cases in each of
the deciles of patients was not statistically different suggesting good
calibration (P = 0.76, chi-square test).
(a) Model
AUC
(c-statistic)
AUC
(cross-validation) Optimism
Donor age 0.78 0.74 0.04
LCN2, HAVCR1 0.80 0.71 0.09
LCN2, HAVCR1
and donor age
0.83 0.75 0.08
(b) Group
Total number
of patients
DGF PF
Observed Expected Observed Expected
1 3 0 0.20 3 2.80
2 3 0 0.46 3 2.54
3 3 1 0.79 2 2.21
4 3 2 1.06 1 1.94
5 3 1 1.30 2 1.70
6 3 2 1.64 1 1.36
7 3 2 1.91 1 1.09
8 3 2 2.28 1 0.72
9 3 3 2.66 0 0.34
10 2 2 2.77 1 0.23
AUC, area under the curve; LCN2, lipocalin 2; HAVCR1, kidney injury
molecule 1; PF, primary function; DGF, delayed graft function.
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Figure S1 Bias test of pre-amplification technique:
Dilution series from a microdissected nephrectomy sam-
ple (T: Tubulointerstium, G: glomeruli part) were mea-
sured with qRT-PCR for ACTB (b-actin), LCN2
(lipocalin 2) and PPIA (Cyclophilin A) after a 10-cycle
pre-amplification.
Figure S2 Bias test for reverse transcription, pre-ampli-
fication and real-time PCR of the reference RNA: Correla-
tion of 14 different genes in the standard RNA
(Stratagene human reference RNA) is almost one suggest-
ing reference RNA is an excellent calibrator.
Table S1. Multivariable logistic regression model:
LCN2 and HAVCR1.
Table S2. Multivariable logistic regression model:
Donor age, cold ischemic time (CIT), panel reactive anti-
bodies (PRA), donor last creatinine, LCN2 and HAVCR1.
Table S3. Multivariable logistic regression model:
Donor age, cold ischemic time (CIT), panel reactive anti-
bodies (PRA) and donor last creatinine.
Please note: Wiley-Blackwell is not responsible for the
content or functionality of any supporting materials sup-
plied by the authors. Any queries (other than missing
material) should be directed to the corresponding author
for the article.
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